HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Gotthardt, M. Articles by Behr, T. M Search for Related Content PubMed PubMed Citation Articles by Gotthardt, M. Articles by Behr, T. M

Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Postbus 9101, 6500 HB Nijmegen, The Netherlands
¹ Department of Nuclear Medicine,
² Institute of Theoretical Surgery,
³ Departments of Gastroenterology and Endocrinology and
⁴ Diagnostic Radiology, Philipps-University of Marburg, Baldingerstrasse, 35043 Marburg, Germany

(Requests for offprints should be addressed to M Gotthardt; Email: m.gotthardt{at}nucmed.umcn.nl)

Gastrin receptor scintigraphy (GRS) is a new imaging method primarily developed for the detection of metastases of medullary thyroid carcinoma (MTC). As gastrin-binding CCK₂ receptors are also expressed on a variety of other neuroendocrine tumours (NET), we compared GRS to somatostatin receptor scintigraphy (SRS) in patients with NET. SRS and GRS were performed within 21 days in a series of 60 consecutive patients with NET. GRS was directly compared with SRS. If lesions were visible on GRS but not detectable by SRS, other imaging modalities (MRI, CT) and follow-up were used for verification. Of the 60 evaluable patients, 51 had carcinoid tumours, 3 gastrinomas, 2 glucagonomas, 1 insulinoma and 3 paragangliomas. The overall tumour-detection rate was 73.7% for GRS and 82.1% for SRS. In the 11 patients with negative SRS, GRS was positive in 6 (54.5%). Based on the number of tumour sites detected and the degree of uptake, GRS performed better than SRS in 13 patients (21.7%), equivalent images were obtained in 18 cases (30.0%) and SRS performed better in 24 (40.0%) cases. In six of the SRS positive patients, 18 additional sites of tumour involvement could be detected. Overall, GRS detected additional tumour sites in 20% of the patients. Localisation of the primary tumours or their functional status had no influence on the outcome of imaging. GRS should be performed in selected patients as it may provide additional information in patients with NET with equivocal or absent somatostatin uptake.

This article has been cited by other articles:

				J. C. Reubi and H. R. Maecke Peptide-Based Probes for Cancer Imaging J. Nucl. Med., November 1, 2008; 49(11): 1735 - 1738. [Abstract] [Full Text] [PDF]

				M. Gotthardt, J. van Eerd-Vismale, W. J.G. Oyen, M. de Jong, H. Zhang, E. Rolleman, H. R. Maecke, M. Behe, and O. Boerman Indication for Different Mechanisms of Kidney Uptake of Radiolabeled Peptides J. Nucl. Med., April 1, 2007; 48(4): 596 - 601. [Abstract] [Full Text] [PDF]